Launch 18 Jan 2024 · costs from the KID as of 2 Sept 2026 · 129 securities held · 9 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
Investment Objective: The Sub-Fund aims to achieve a long-term return in excess of Russell 1000 Growth Index (Net Total Return of 30% dividend withholding tax) ("the Benchmark") by actively investing primarily in a growth style-biased portfolio of US Companies.
Investment Policy:
The Sub-Fund pursues an actively-managed investment strategy. The Sub-Fund aims to invest at least 67% of its assets (excluding assets held for ancillary liquidity purposes) in equity securities issued primarily by companies that are domiciled in, or carrying out the main part…
Performance since series start (in euro) — base 100
18 Jan 2024 → 3 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
High 153 (30 Jun 2026) · low 100 (18 Jan 2024) · last 143. Past performance is not indicative of future results.
The live sheet, always up to date rebalix.com/en/etf/IE0005CH3U28 Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.